Ultragenyx Pharmaceutical, Inc. (RARE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Ultragenyx Pharmaceutical, Inc. (RARE)
Company Performance

Current Price

as of Oct 16, 2024

$57.70

P/E Ratio

N/A

Market Cap

$5.32B

Description

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Metrics

Overview

  • HQNovato, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerRARE
  • Price$57.7+1.02%

Trading Information

  • Market Cap$5.32B
  • Float93.54%
  • Average Daily Volume (1m)634,283
  • Average Daily Volume (3m)691,736
  • EPS-$7.29

Company

  • Revenue$481.30M
  • Rev Growth (1yr)35.75%
  • Net Income-$131.60M
  • Gross Margin79.50%
  • EBITDA Margin-73.12%
  • EBITDA-$107.50M
  • EV$3.72B
  • EV/Revenue7.72
  • P/EN/A
  • P/S10.38
  • P/B12.29
Documents
SEC Filings
8-K (2024-10-07)
8-K (2024-10-03)
8-K (2024-08-01)
8-K (2024-07-17)
8-K (2024-06-21)
8-K (2024-06-17)
8-K (2024-06-12)
8-K (2024-05-30)
8-K (2024-05-02)
8-K (2024-04-15)
8-K (2024-02-15)
8-K (2024-01-08)
8-K (2023-12-21)
8-K (2023-11-02)
8-K (2023-10-23)
8-K (2023-10-16)
8-K (2023-09-08)
8-K (2023-08-03)
8-K (2023-07-12)
8-K (2023-07-06)
8-K (2023-06-13)
8-K (2023-06-05)
8-K (2023-05-17)
8-K (2023-05-04)
8-K (2023-03-23)
8-K (2023-03-14)
8-K (2023-02-16)
8-K (2023-01-06)
10-Q (2024-08-02)
10-Q (2024-05-03)
10-Q (2023-11-03)
10-Q (2023-08-04)
10-Q (2023-05-05)
10-K (2024-02-21)
10-K (2023-02-17)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-02)
Earnings Report (2023-08-03)
Factset Street Account
Ultragenyx, Mereo BioPharma present interim Phase 2 data from Orbit study of setrusumab at ASBMR ($33.57, 0.00) (2023-10-14T21:53:03Z)
Ultragenyx receives EC decision for Evkeeza (evinacumab) expanded indication in children aged 5 years and older with homozygous familial hypercholesterolemia (HoFH) ($45.97, 0.00) (2023-12-18T13:06:28Z)
Ultragenyx Pharmaceutical reports Q3 EPS ($2.23) vs FactSet ($2.08) [17 est, ($2.71)-(1.55)] ($36.70, 0.00) (2023-11-02T20:09:54Z)
StreetAccount Earnings Call Q&A Summary: Ultragenyx Pharmaceutical Q3 ($ 36.60, 0.00) (2023-11-02T23:58:08Z)
EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Evkeeza ($34.95, 0.00) (2023-11-10T12:57:40Z)
Factset
Factset Business Description
Wikipedia
Ultragenyx_Pharmaceutical_Inc.